President Trump announced a White House deal with Novo Nordisk and Eli Lilly to sharply lower prices and expand access to Wegovy, Zepbound and forthcoming obesity pills. Lowest-dose pills will cost $149 a month; current direct-to-consumer prices for weekly injections average about $350, with officials expecting $245 within two years. Medicare and Medicaid coverage will broaden next year at roughly $245 a month for eligible patients, with Medicare co-pays capped at $50. The rollout includes a TrumpRx.gov portal and accelerated FDA reviews. The event paused briefly after a man collapsed.

Prepared by Christopher Adams and reviewed by editorial team.